UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2017, Volume 152, Issue 5, pp. 1078 - 1089
Gastroenterology and Hepatology | Side Effect | Medication | Liver Damage | Anti-Fungal Agent | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Antifungal Agents - adverse effects | Naphthalenes - adverse effects | Humans | Middle Aged | Male | Sertraline - adverse effects | Fenofibrate - adverse effects | Chromosomes, Human, Pair 2 - genetics | Ticlopidine - adverse effects | Female | Odds Ratio | Chemical and Drug Induced Liver Injury - etiology | Platelet Aggregation Inhibitors - adverse effects | Hypolipidemic Agents - adverse effects | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Genes, MHC Class I - genetics | Chemical and Drug Induced Liver Injury - genetics | Terbinafine | Phenotype | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Alleles | HLA-A Antigens - genetics | Polymorphism, Single Nucleotide | Antidepressive Agents - adverse effects | Drugs | Medical research | Liver diseases | Liver | Genes | Genomics | Risk factors | Genetic polymorphisms | Analysis | Gastrointestinal diseases | Medicine, Experimental | Genetic research | Trade and professional associations | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Hépatology and Gastroenterology | side effect | medication | anti-fungal agent | liver damage
Journal Article
The New England journal of medicine, ISSN 0028-4793, 04/2010, Volume 362, Issue 17, pp. 1563 - 1574
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Simvastatin - therapeutic use | Myocardial Infarction - epidemiology | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Male | Fenofibrate - therapeutic use | Fenofibrate - adverse effects | Treatment Failure | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Drug Therapy, Combination | Hypolipidemic Agents - adverse effects | Stroke - prevention & control | Kaplan-Meier Estimate | Proportional Hazards Models | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Sex Factors | Triglycerides - blood | Aged | Hypolipidemic Agents - therapeutic use | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Evaluation | Complications and side effects | Usage | Dosage and administration | Drug therapy, Combination | Drug therapy | Health aspects | Statins | Fibric acids | Cardiovascular disease | Lipids | Diabetes | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
3.
Full Text
Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics
Clinical pharmacology and therapeutics, ISSN 0009-9236, 05/2016, Volume 99, Issue 5, pp. 538 - 547
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypoglycemia - epidemiology | Glipizide - administration & dosage | Humans | Middle Aged | Glipizide - adverse effects | Male | Fenofibrate - adverse effects | Incidence | Drug Interactions | Hypoglycemic Agents - administration & dosage | Female | Retrospective Studies | Sulfonylurea Compounds - administration & dosage | Glyburide - administration & dosage | Hypoglycemia - chemically induced | Glyburide - adverse effects | Severity of Illness Index | Hypolipidemic Agents - adverse effects | Fenofibrate - administration & dosage | Sulfonylurea Compounds - adverse effects | Algorithms | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hypolipidemic Agents - administration & dosage | Aged | Hypoglycemic Agents - adverse effects | Cohort Studies | Care and treatment | Dosage and administration | Management | Hypoglycemia | Hypoglycemic sulfonylureas | Sulfonylurea compounds | Risk factors | Public health | Index Medicus | Abridged Index Medicus | drug interactions | fibric acids | sulfonylurea compounds | hypoglycemia | cohort studies | hydroxymethylglutaryl-CoA reductase inhibitors | Medicaid | pharmacoepidemiology | propensity score
Journal Article
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1079-5642, 06/2014, Volume 34, Issue 6, pp. 1298 - 1306
hypertriglyceridemia | atorvastatin | carotid intima-media thickness | fenofibric acid | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Dyslipidemias - drug therapy | Double-Blind Method | Carotid Intima-Media Thickness | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Fenofibrate - analogs & derivatives | Male | Heptanoic Acids - adverse effects | Dyslipidemias - pathology | Fenofibrate - adverse effects | Atorvastatin Calcium | Dyslipidemias - blood | Fenofibrate - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Index Medicus
Journal Article
06/2000, Volume 22, Issue 6, 17
HMG CoA reductase inhibitors, adverse reactions | Lovastatin, adverse reactions | Pravastatin, adverse reactions | Arthralgia, drug-induced | Muscle pain, drug-induced | HMG CoA reductase inhibitors, drug interactions | HMG CoA reductase inhibitors, pharmacokinetics | Simvastatin, adverse reactions | Drug interactions | Cerivastatin, adverse reactions | Clofibrate, adverse reactions | Muscular disorders, drug-induced | Cholestyramine, adverse reactions | Colestipol, adverse reactions | Myositis, drug-induced | Fluvastatin, adverse reactions | Rhabdomyolysis, drug-induced | Nicotinic acid, adverse reactions | Fenofibrate, adverse reactions | Atorvastatin, adverse reactions | Bezafibrate, adverse reactions | Gemfibrozil, adverse reactions | Pharmacology & Pharmacy | Public, Environmental & Occupational Health | Toxicology | Life Sciences & Biomedicine | Science & Technology | Biological and medical sciences | Toxicity: nervous system and muscle | Medical sciences | Drug toxicity and drugs side effects treatment | Pharmacology. Drug treatments | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Risk Factors | Muscular Diseases - pathology | Muscular Diseases - chemically induced | Index Medicus
Book Review
Current medical research and opinion, ISSN 0300-7995, 03/2013, Volume 29, Issue 3, pp. 181 - 188
Fenofibric acid | Statin | Adverse events | Meta-analysis | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Biological and medical sciences | Medical sciences | Drug toxicity and drugs side effects treatment | General and cellular metabolism. Vitamins | Pharmacology. Drug treatments | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypolipidemic Agents - adverse effects | Dyslipidemias - drug therapy | Kidney - drug effects | Creatine Kinase - blood | Lipoproteins, HDL - blood | Humans | Fenofibrate - administration & dosage | Fenofibrate - analogs & derivatives | Alanine Transaminase - blood | Fenofibrate - therapeutic use | Fenofibrate - adverse effects | Randomized Controlled Trials as Topic | Drug Therapy, Combination - adverse effects | Dyslipidemias - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Aspartate Aminotransferases - blood | Liver - drug effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Lipids - blood | Hypolipidemic Agents - administration & dosage | Triglycerides - blood | Hypolipidemic Agents - therapeutic use | Lipoproteins, LDL - blood | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 23, pp. 2171 - 2181
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Bezafibrate - therapeutic use | Hypolipidemic Agents - adverse effects | Bile Acids and Salts - blood | Double-Blind Method | Humans | Middle Aged | Liver Cirrhosis, Biliary - drug therapy | Male | Bezafibrate - adverse effects | Cholangitis - drug therapy | Ursodeoxycholic Acid - therapeutic use | Cholangitis - etiology | Placebos - therapeutic use | Treatment Failure | Adult | Female | Hypolipidemic Agents - therapeutic use | Liver Cirrhosis, Biliary - complications | Usage | Care and treatment | Dosage and administration | Biliary cirrhosis | Research | Health aspects | Fibric acids | Antilipemic agents | Alkaline phosphatase | Laboratories | Liver | Gallbladder diseases | Biochemistry | Pruritus | Bilirubin | Phosphatase | Ursodeoxycholic acid | Hepatitis | Hepatology | Gastroenterology | Tumor necrosis factor-TNF | Creatinine | Hypertension | Liver diseases | Cholangitis | Fatigue | Myalgia | Patients | Cholesterol | Quality of life | Hospitals | Acids | Bezafibrate | Fibrosis | Prothrombin | Peroxisome proliferator-activated receptors | Bile | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
The American journal of cardiology, ISSN 0002-9149, 2004, Volume 94, Issue 7, pp. 935 - 938
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Medical sciences | Hypolipidemic Agents - adverse effects | United States - epidemiology | Rhabdomyolysis - epidemiology | Humans | Hyperlipidemias - drug therapy | Middle Aged | Risk Factors | Male | Liver Diseases - epidemiology | Gemfibrozil - adverse effects | Fenofibrate - adverse effects | Treatment Failure | Rhabdomyolysis - chemically induced | Female | Aged | Chemical and Drug Induced Liver Injury | Complications and side effects | Gemfibrozil | Fibric acids | Cardiology | Drug therapy | Risk assessment | Index Medicus | Abridged Index Medicus
Journal Article